CytomX Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing conditionally activated, masked biologics using its PROBODY technology platform. The platform masks biologic therapeutics until tumor-associated proteases remove the mask in the tumor microenvironment. Its lead program, Varseta-M (varsetatug masetecan), is an EpCAM-targeting ADC in Phase 1 for metastatic colorectal cancer. CX-801 is a second clinical program. The company licenses payload technology from AbbVie (formerly ImmunoGen).
Q2 FY2026 — expected 2026-08-08
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-16 | 2025-12-31 | 0001193125-26-107146 | EDGAR | 99K words |
| 2025-03-06 | 2024-12-31 | 0000950170-25-034575 | EDGAR | 94K words |
| 2024-03-11 | 2023-12-31 | 0000950170-24-029191 | EDGAR | 95K words |
| 2023-03-27 | 2022-12-31 | 0000950170-23-009991 | EDGAR | 102K words |
| 2022-03-01 | 2021-12-31 | 0000950170-22-002519 | EDGAR | — |
| 2021-02-24 | 2020-12-31 | 0001564590-21-008081 | EDGAR | — |
| 2020-02-27 | 2019-12-31 | 0001564590-20-007395 | EDGAR | — |
| 2019-02-27 | 2018-12-31 | 0001564590-19-004890 | EDGAR | — |
| 2018-03-07 | 2017-12-31 | 0001564590-18-004727 | EDGAR | — |
| 2017-03-02 | 2016-12-31 | 0001564590-17-003229 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-06 | 2026-06-30 | 0001193125-26-337950 | EDGAR | 61K words |
| 2025-11-06 | 2025-09-30 | 0001193125-25-269477 | EDGAR | 61K words |
| 2025-08-07 | 2025-06-30 | 0000950170-25-104991 | EDGAR | 59K words |
| 2025-05-12 | 2025-03-31 | 0000950170-25-068511 | EDGAR | 58K words |
| 2024-11-07 | 2024-09-30 | 0000950170-24-123249 | EDGAR | 61K words |
| 2024-08-08 | 2024-06-30 | 0000950170-24-093865 | EDGAR | 60K words |
| 2024-05-08 | 2024-03-31 | 0000950170-24-055588 | EDGAR | 58K words |
| 2023-11-07 | 2023-09-30 | 0000950170-23-060201 | EDGAR | 62K words |
| 2023-08-08 | 2023-06-30 | 0000950170-23-039761 | EDGAR | 60K words |
| 2023-05-09 | 2023-03-31 | 0000950170-23-019654 | EDGAR | 58K words |
| 2022-11-08 | 2022-09-30 | 0000950170-22-023190 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0000950170-22-014737 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-06 | 0001193125-26-338009 | EDGAR | 3K words |
| 2026-07-27 | 0001193125-26-316929 | EDGAR | 1K words |
| 2026-03-19 | 0001193125-26-115958 | EDGAR | 29K words |
| 2026-03-16 | 0001193125-26-107152 | EDGAR | 3K words |
| 2025-11-06 | 0001193125-25-269533 | EDGAR | 3K words |
| 2025-08-13 | 0001193125-25-179463 | EDGAR | 1K words |
| 2025-08-07 | 0000950170-25-105053 | EDGAR | 3K words |
| 2025-06-13 | 0001193125-25-140739 | EDGAR | 9K words |
| 2025-05-28 | 0001193125-25-129470 | EDGAR | 1K words |
| 2025-05-13 | 0001193125-25-118805 | EDGAR | 19K words |
210 total filings indexed. 178 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001501989 |
| Ticker | CTMX |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.cytomx.com |
| Listed | 2015-10-08 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/CTMX (~200 tokens, structured JSON with cryptographic provenance)